---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042951"
form_type: "8-K"
ticker: "WGRX"
cik: "0002030763"
company_name: "Wellgistics Health, Inc."
filed_at: "2026-09-16T21:11:55+00:00"
generated_at: "2026-09-16T21:14:12.367731+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DataMeds acquires Helomics for $1.5M in stock and convertible note, expanding into cancer diagnostics

## Summary
- Paid 636,328 shares (~19.99% of MEDS outstanding) plus $1.363M 7% convertible note due Sept 2029; conversion at $1.00/share pending Nasdaq approval.
- Helomics brings CLIA/CAP-certified lab, Predictive Oncology CRO, and $1.5M cash; no third-party debt or unpaid payables.
- Expands DataMEDS beyond GLP-1 and Long COVID into $40B U.S. cancer diagnostic/treatment market.
- Seller Axe Compute (AGPU) retains shareholder stake; agrees to 12-month transfer lock-up and 6-month vote-alignment with DataMeds board.
- Deal closed Sept 11, 2026; Helomics becomes wholly owned subsidiary of DataMeds AI.

## SEC filing metadata
- accession: 0001493152-26-042951
- form_type: 8-K
- ticker: WGRX
- cik: 0002030763
- company_name: Wellgistics Health, Inc.
- filed_at: 2026-09-16T21:11:55+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030763/000149315226042951/0001493152-26-042951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030763/000149315226042951/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042951
- JSON: https://secwatch.observer/filing/0001493152-26-042951.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.